A detailed history of Asset Dedication, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Asset Dedication, LLC holds 4,167 shares of GILD stock, worth $345,110. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,167
Previous 5,877 29.1%
Holding current value
$345,110
Previous $432,000 34.03%
% of portfolio
0.02%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$63.15 - $72.88 $107,986 - $124,624
-1,710 Reduced 29.1%
4,167 $285,000
Q1 2024

Apr 16, 2024

SELL
$71.58 - $87.29 $62,775 - $76,553
-877 Reduced 12.98%
5,877 $432,000
Q4 2023

Feb 08, 2024

BUY
$73.27 - $83.09 $59,568 - $67,552
813 Added 13.68%
6,754 $545,000
Q3 2023

Nov 13, 2023

SELL
$73.94 - $80.67 $5,397 - $5,888
-73 Reduced 1.21%
5,941 $450,000
Q2 2023

Aug 21, 2023

BUY
$76.01 - $86.7 $21,586 - $24,622
284 Added 4.96%
6,014 $464,000
Q1 2023

Apr 21, 2023

BUY
$77.31 - $88.08 $22,883 - $26,071
296 Added 5.45%
5,730 $470,000
Q4 2022

Jan 19, 2023

BUY
$62.32 - $89.47 $36,083 - $51,803
579 Added 11.93%
5,434 $465,000
Q3 2022

Oct 27, 2022

BUY
$59.54 - $68.01 $289,066 - $330,188
4,855 New
4,855 $301,000
Q2 2022

Jul 19, 2022

SELL
$57.72 - $65.01 $154,862 - $174,421
-2,683 Closed
0 $0
Q1 2022

Apr 21, 2022

SELL
$57.92 - $72.58 $308,308 - $386,343
-5,323 Reduced 66.49%
2,683 $160,000
Q4 2021

Jan 21, 2022

SELL
$64.88 - $73.64 $38,279 - $43,447
-590 Reduced 6.86%
8,006 $581,000
Q3 2021

Oct 18, 2021

BUY
$67.69 - $73.03 $103,362 - $111,516
1,527 Added 21.6%
8,596 $599,000
Q2 2021

Jul 21, 2021

BUY
$63.47 - $69.35 $245,311 - $268,037
3,865 Added 120.63%
7,069 $486,000
Q1 2021

May 03, 2021

BUY
$60.0 - $68.46 $12,600 - $14,376
210 Added 7.01%
3,204 $205,000
Q4 2020

Jan 28, 2021

BUY
$56.65 - $64.55 $45,093 - $51,381
796 Added 36.21%
2,994 $175,000
Q3 2020

Oct 20, 2020

SELL
$62.1 - $78.08 $389,801 - $490,108
-6,277 Reduced 74.06%
2,198 $139,000
Q2 2020

Aug 24, 2020

BUY
$72.34 - $84.0 $79,791 - $92,652
1,103 Added 14.96%
8,475 $652,000
Q1 2020

May 05, 2020

BUY
$62.63 - $80.22 $87,118 - $111,586
1,391 Added 23.26%
7,372 $553,000
Q4 2019

Jan 31, 2020

SELL
$61.62 - $67.78 $156,453 - $172,093
-2,539 Reduced 29.8%
5,981 $389,000
Q3 2019

Oct 17, 2019

BUY
$62.51 - $69.0 $18,065 - $19,941
289 Added 3.51%
8,520 $541,000
Q2 2019

Jul 23, 2019

BUY
$61.87 - $69.38 $86,246 - $96,715
1,394 Added 20.39%
8,231 $552,000
Q1 2019

Apr 19, 2019

BUY
$62.53 - $70.05 $23,323 - $26,128
373 Added 5.77%
6,837 $440,000
Q4 2018

Feb 12, 2019

SELL
$60.54 - $79.0 $36,687 - $47,874
-606 Reduced 8.57%
6,464 $405,000
Q3 2018

Oct 26, 2018

BUY
$71.28 - $78.92 $31,363 - $34,724
440 Added 6.64%
7,070 $538,000
Q2 2018

Aug 13, 2018

BUY
$64.88 - $75.68 $5,255 - $6,130
81 Added 1.24%
6,630 $476,000
Q1 2018

Apr 19, 2018

BUY
$72.84 - $88.8 $58,344 - $71,128
801 Added 13.94%
6,549 $490,000
Q4 2017

Jan 17, 2018

BUY
$71.15 - $83.52 $264,749 - $310,777
3,721 Added 183.57%
5,748 $416,000
Q3 2017

Oct 18, 2017

BUY
$72.11 - $85.47 $146,166 - $173,247
2,027
2,027 $163,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $104B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Asset Dedication, LLC Portfolio

Follow Asset Dedication, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Dedication, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Asset Dedication, LLC with notifications on news.